Diagnostic Role of Survivin in Urinary Bladder Cancer

  • Published : 2013.01.31


Background: Early diagnosis of carcinoma of bladder remains a challenge. Survivin, a member of the inhibitor of apoptosis (IAP) protein family, is frequently activated in bladder carcinoma. The objective of this study was to investigate urinary survivin as a marker for diagnosis of urinary bladder. Materials and Methods: We examined urinary survivin concentration in 28 healthy individuals, 46 positive controls and 117 cases of histologically proven TCC prior to transurethral resection, using ELISA, and compared values with findings for urinary cytology. Results: Survivin was found to be significantly higher in the cancer group (P<0.05). A cut off value of 17.7 pg/ml was proposed, with an approximate sensitivity of 82.9% and specificity of 81.1% (P<0.0001), whereas urine cytology had a sensitivity of 66.7% and a specificity of 96.0%. Conclusions: Urinary survivin can be used as a non-invasive diagnostic biomarker for TCC bladder, both for primary and recurrent disease.


  1. Kausch I, Bohle A (2001). Bladder cancer. II. Molecular aspects and diagnosis. Eur Urol, 39, 498-506.
  2. Konety BR, Getzenberg RH (2001). Urine based markers of urological malignancy. J Urol, 165, 600-11.
  3. Lokeshwar VB, Soloway MS (2001). Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol, 165, 1067-77.
  4. Ohsawa I, Nishimura T, kondo Y, et al (2004). Detection of urine survivin in 40 patients with bladder cancer. J Nippon Med Sch, 71, 379-83.
  5. Rodel F, Hoffmann J, Grabenbauer GG, et al (2002). High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol, 178, 426-35.
  6. Ryan BM, Konecny GE, Kahlert S, et al (2006). Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol, 17, 597-04.
  7. Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011. the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 61, 212-36.
  8. Swana HS, Grossman D, Anthony JN, et al (1999). Tumor content of the antiapoptotic molecule SURVIVIN and recurrence of bladder cancer. N Engl J Med, 34, 1452-53.
  9. Smith SD, Wheeler MA, Plescia J, et al (2001). Urine detection of survivin and diagnosis of bladder cancer. JAMA, 285, 324-8.
  10. Shariat SF, Casella R, Khoddami SM, et al (2004). Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. Urol, 171, 626-30.
  11. Sobin LH, Wittekind CL (2002). TNM classification of malignant tumors, 6th edition. John Wiley & Sons, New York.
  12. SUN Yi, HE Da-lin, MA Qiang, et al (2006). Comparison of seven screening methods in the diagnosis of bladder cancer. Chinese Med J, 119, 1763-71.
  13. Sharp JD, Hausladen DA, Maher MG, et al (2002). Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Front Biosci, 7, 36-41.
  14. Uren AG, Wong L, Pakusch M, et al (2000). Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol, 10, 1319-28.
  15. Viv Bewick, Liz Cheek, Jonathan Ball (2004). Statistics review 13: Receiver operating characteristic curves. Critical Care, 8, 508-12.
  16. Wang T, Qian X, Liu B (2007). Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J Gastroenterol, 13, 2784-90.
  17. Weikert S, Christoph F, Schrader M, et al (2005) Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer, 116, 100-04.
  18. Walsh PC, Retik Ab, Vaughn ED, et al (1997) Campbell's Urology. Philadelphia, WB Saunders, Co., 2354-57.
  19. Agarwal PK, Black PC, Kamat AM (2008). Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol, 26, 39-44.
  20. Ambrosini G, Adida C, Altieri D (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med, 3, 917-21.
  21. Altieri DC (2003). Survivin in apoptosis control and cell cycle regulation in cancer. Progress in Cell Cycle Res, 5, 447-52.
  22. Azuhata T, Scott D, Takamizawa S, et al (2001). The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg, 36, 1785-91.
  23. Boman H, Hedelin H, Holmang S, (2002). Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol, 16, 780-3.
  24. Brown FM (2000). Urine cytology. It is still the gold standard for screening? Urol Clin North Am, 27, 25-37.
  25. Davido HT, Getzenberg RH (2002). Utilization of a urine-based assay for BLCA-4 in the detection of bladder cancer. J Clinical Ligand Assay, 25, 83-6.
  26. Epstein JI, Amin MB, Reuter VR, et al (1998). The world health organization/international society of urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. bladder consensus conference committee. Am J Surg Pathol, 22, 1435-48.
  27. Fritz A, Percy C, Jack A, et al (2000). International Classification of Diseases for Oncology, 3rd edition, World Health Organization, Geneva.
  28. Fuessel S, Kueppers B, Ning S, et al (2004). Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol, 171, 2471-6.
  29. Grossfeld GD, Carroll PR (1998). Evaluation of asymptomatic microscopic hematuria. Urol Clin N Am, 25, 661-76.
  30. Goebell PJ, Groshen SL, Schmitz-Drager BJ (2008). Guidelines for development of diagnostic markers in bladder cancer. World J Urol, 26, 5-11.
  31. Giodini A, Kallio MJ, Wall NR, et al (2002). Regulation of microtubule stability and mitotic progression by survivin. Cancer Res, 62, 2462-7.
  32. Ikeguchi M, Kaibara N (2002). Survivin, messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Bri J Cancer, 87, 883-7.

Cited by

  1. Can Reproductive Characteristics Predict Bladder Cancer in Women with Haematuria? vol.14, pp.9, 2013,
  2. RASSF1A Suppresses Proliferation of Cervical Cancer Cells vol.15, pp.14, 2014,
  3. Lack of Relation of Survivin Gene Expression with Survival and Surgical Prognostic Factors in Endometrial Carcinoma Patients vol.15, pp.16, 2014,
  4. Bladder Cancer Biomarkers: Review and Update vol.15, pp.6, 2014,
  5. Clinical Significance of Survivin Expression in Patients with Urothelial Carcinoma vol.2014, pp.1875-8630, 2014,
  6. Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder vol.35, pp.8, 2014,
  7. Bladder cancer biomarker array to detect aberrant levels of proteins in urine vol.140, pp.3, 2015,
  8. Can Recurrence and Progression be Predicted by HYAL-1 Expression in Primary T1 Bladder Cancer? vol.15, pp.23, 2015,
  9. Expression of survivin in squamous cell carcinoma and transitional cell carcinoma of the urinary bladder: A comparative immunohistochemical study vol.56, pp.1, 2015,
  10. Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer vol.18, pp.12, 2017,
  11. Validation of a protein panel for the noninvasive detection of recurrent non-muscle invasive bladder cancer pp.1366-5804, 2017,
  12. Validation of the diagnostic utility of urinary midkine for the detection of bladder cancer vol.12, pp.5, 2016,
  13. Microplate magnetic chemiluminescence immunoassay for detecting urinary survivin in bladder cancer vol.14, pp.4, 2017,
  14. Evaluation of a New Survivin ELISA and UBC® Rapid for the Detection of Bladder Cancer in Urine vol.19, pp.1, 2018,
  15. Diagnostic value of urinary survivin as a biomarker for bladder cancer: a systematic review and meta-analysis of published studies vol.36, pp.9, 2018,